New Mismatch Repair Test Identifies Patients for Pembrolizumab New Mismatch Repair Test Identifies Patients for Pembrolizumab

The Ventana panel for DNA mismatch repair (MMR) is now approved to identify patients suitable for treatment with pembrolizumab (Keytruda).FDA Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news